Why Myriad Genetics (MYGN) Shares Are Falling Today
Myriad Genetics (MYGN) shares fell 46.1% after the company reported Q2 2026 results that missed Wall Street expectations and cut its full-year forecast. Revenue was $190.7 million, down 10.5% year over year, with an adjusted loss per share of $0.25. Full-year revenue guidance was reduced to a $780 million midpoint.
How this was made
The 30-second read
Why it matters
A large earnings and guidance miss typically forces analysts to revise models and can trigger additional selling from holders with near-term expectations.
Market read
The market is repricing Myriad’s forward revenue path after a sharp guidance reduction and wider adjusted loss, producing a high-volatility trading setup.
What to watch
The article does not discuss cash balance, cost actions, or segment-level drivers for the miss, which could materially change the forward outlook versus the headline guidance cut.
Background
Myriad Genetics previously reported a strong Q2 with raised full-year guidance and a new $200M credit facility, but this quarter reverses that trajectory.
Ticker impact
Myriad Genetics shares fell 46.1% after Q2 2026 results missed expectations and the company cut full-year revenue guidance to a $780M midpoint.
Bearish near-term bias, with elevated volatility likely to persist as the market reprices forward revenue and margin expectations.
The article cites multiple concrete downside datapoints: revenue down 10.5% YoY to $190.7M, adjusted loss per share of $0.25, and a >10% full-year revenue guidance reduction to a $780M midpoint.
Market effects
Signals pressure on genetic testing peers if investors generalize weaker demand or reimbursement dynamics.
Primarily US small/mid-cap biotech/genetic testing sentiment impact via a large single-name drawdown.
Limited direct global spillover, but it can affect investor appetite for precision medicine testing exposure.
Counterpoint
The stock’s extreme drawdown could reflect an overreaction if the guidance cut is temporary and driven by timing rather than structural demand deterioration.
Key entities
- companyMyriad Genetics
Genetic testing company whose Q2 2026 results missed expectations and whose full-year revenue guidance was reduced.
